Prostate Cancer

Latest News

Blur image of hospital corridor | Image Credit: © whyframeshot - stock.adobe.com
Darolutamide is safe, efficacious in mHSPC regardless of patient age

February 13th 2025

"Patients with metastatic hormone-sensitive prostate cancer benefited from treatment with darolutamide plus ADT and docetaxel regardless of age," said Joan Carles, MD, PhD.

Conceptual image for prostate cancer treatment, 3D illustration showing destruction of a tumor inside prostate gland | © Dr_Microbe - stock.adobe.com
Race subgroup analysis points to clinical benefit of darolutamide in nmCRPC

February 13th 2025

Conceptual image for viral ethiology of prostate cancer | © Dr_Microbe - stock.adobe.com
STOPCAP: ARPIs benefit younger patients with mHSPC

February 13th 2025

TALAPRO-2: Talazoparib/enzalutamide confers significant OS benefit in mCRPC
TALAPRO-2: Talazoparib/enzalutamide confers significant OS benefit in mCRPC

February 13th 2025

FDA grants 510(k) clearance to AI-powered prostate cancer diagnostic
FDA grants 510(k) clearance to AI-powered prostate cancer diagnostic

February 10th 2025

More News

© 2025 MJH Life Sciences

All rights reserved.